| Open Document File Size: 2,21 MBShare Result on Facebook
City South San Francisco / Nutley / / Company Roche Laboratories Inc. / Genentech USA Inc. / / Country Japan / / Event FDA Phase / / / IndustryTerm treatment of acute / uncomplicated illness / appropriate dosing device / / MedicalCondition Important Safety Information Severe Allergic Reactions / severe allergic reactions / abdominal pain / influenza infection / Bacterial Infections / chronic cardiac disease / hallucinations / nausea / anaphylaxis / toxic epidermal necrolysis / ear disorder / Stevens-Johnson syndrome / Vomiting / obvious severe disease / injury / encephalopathy / acute / uncomplicated illness / encephalitis / Influenza viruses / erythema multiforme / diaper rash / delirium / diarrhea / illness / respiratory disease / acute / uncomplicated influenza / early and active influenza / influenza / Neurologic Symptoms / live attenuated influenza vaccine / / MedicalTreatment vaccination / / Organization Centers for Disease Control and Prevention Advisory Committee on Immunization Practices / FDA / / Person Hal Barron / / / Position Member of the Roche Group / physician / / Product Tamiflu / Impact / Genentech Branding Description Branding Color Scheme Capsule / Genentech Oral Suspension / Oral Suspension / patients / / ProvinceOrState New Jersey / California / / URL http /
SocialTag |
Dear Healthcare Provider Letter for Tamiflu